News & insights

R 12/21: Petition for review succeeds after EPO Board of Appeal found to violate right to be heard

Thoughts

R 12/21: Petition for review succeeds after EPO Board of Appeal found to violate right to be heard

The petition for review procedure under Article 112a EPC allows parties adversely affected by a decision of the Board of Appeal (BoA) to request a review by the Enlarged Board of Appeal (EBoA). The ba...

The CRISPR therapeutics landscape in 2025

CRISPR

The CRISPR therapeutics landscape in 2025

Once confined to science fiction, precise genetic engineering has become a reality and has profoundly impacted modern medicine. CRISPR technology, leveraging guide RNA (gRNA) base pairing to modif...

Dosage regimen patents at the EPO part (II): Recent case law

Case law

Dosage regimen patents at the EPO part (II): Recent case law

Dosage regimen patent applications are typically filed a few years after the original application to compounds and their medical uses. Often a clinical trial will already be underway, investigating di...

Dosage regimen patents at the EPO part (I): Strategic tips for success

Technical Tips

Dosage regimen patents at the EPO part (I): Strategic tips for success

Dosage regimen claims typically refer to compounds for use in treating a condition at a specific frequency of administration, at a specific dose or within a specific dosage range. Sometimes further fe...

Sanofi vs Amgen: The UPC decides on second medical use claims

Case law

Sanofi vs Amgen: The UPC decides on second medical use claims

The Dusseldorf local division has last week handed down the first decision from the UPC relating to second medical use claims. Here, we discuss what can be gleaned from this first instance decision re...

Challenges of extending expired patent rights through trade marks in the medical implant market: Insights from AG Biondi’s Opinion in Case C-17/24

Case law

Challenges of extending expired patent rights through trade marks in the medical implant market: Insights from AG Biondi’s Opinion in Case C-17/24

Trade marks can offer very powerful complementary and long-lasting benefits for companies once their patents expire. The term of protection of a patent can give its owner a precious period in which to...

How RNA therapeutics are shaping the future of mental health treatment

Thoughts

How RNA therapeutics are shaping the future of mental health treatment

This Mental Health Awareness Week, we wanted to highlight how the fast-moving field of RNA therapeutics is being leveraged to treat mental health disorders such as anxiety and depression. We will cove...

Requesting a Unitary Patent – What do I need to know?

Thoughts

Requesting a Unitary Patent – What do I need to know?

Since the changes to the European patent system which led to the introduction of the Unitary Patent (UP) and the Unified Patent Court (UPC), we have been assisting more and more clients with obtaining...

Opposition Hotspots: Which medical technology sectors face the highest rate of EPO opposition?

Thoughts

Opposition Hotspots: Which medical technology sectors face the highest rate of EPO opposition?

Which MedTech sectors see the most oppositions at the EPO? Which MedTech patents are safer from being revoked or limited via EPO opposition?

Let us keep you up to date. If you’d like to receive communications from us, ranging from breaking news to technical updates, thought leadership to event invitations, please let us know.

Connect with us